BAL 101553

Drug Profile

BAL 101553

Alternative Names: BAL-101553; BAL-27862

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Basilea Pharmaceutica
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Preclinical Brain cancer; Breast cancer

Most Recent Events

  • 12 Jun 2017 Basilea Pharmaceutica, in collaboration with the Adult Brain Tumor Consortium, plans a phase I trial for Glioblastoma (Newly diagnosed) in USA, in third quarter of 2017
  • 12 Jun 2017 Basilea Pharmaceutica signs a clinical study agreement with the Adult Brain Tumor Consortium in USA
  • 07 Jun 2017 Phase-I clinical trials in Glioblastoma (Newly diagnosed) in USA (PO) (NCT03250299)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top